Antibody Drug Conjugates Global Market Report 2023 Antibody Drug Conjugates Global Market Report 2023 – By Type (Monoclonal Antibodies, Linker, Drug/Toxin, Other Types), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications), By Product (Adcertis, Kadcyla, Other Products), By Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology), By End User (Hospital, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032 ...(expand)

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell. For further insights on the antibody drug conjugates market, request a sample here

The antibody drug conjugates market growth is aided by rising incidences of cancer globally. However, some antibody drug conjugates market restraints include challenges involved in the manufacturing of ADCs. For further insights on the antibody drug conjugates market, request a sample here

The antibody drug conjugates market is expected to reach $16.15 billion in 2027 at a rate of 22.4%. For further insights on the antibody drug conjugates market, request a sample here

The global antibody drug conjugates market is segmented as
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
3) By Product: Adcertis, Kadcyla, Other Products
4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
5) By End User: Hospital, Clinics, Other End Users
For further insights on the antibody drug conjugates market, request a sample here

North America was the largest region in the antibody drug conjugates market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Key competitors in the antibody drug conjugates market are, Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., ImmunomedicsInc., Oxford BioTherapeutics, Pfizer Inc., Seattle GeneticsInc., Takeda Pharmaceutical Company Limited, Abbvie Inc., Astellas Pharma/Agensys, Oxford BioTherapeutics, AgensysInc., Antikor, Celldex Therapeutics, Genentech, Heidelberg Pharma, Immunomedics, Mersana Therapeutics, Millennium Pharmaceuticals, Progenics Pharmaceuticals, Roche Holding Ag, Synthon. For further insights on the antibody drug conjugates market, request a sample here.

Major trends influencing the antibody drug conjugates market include increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For further insights on the antibody drug conjugates market, request a sample here.

For detailed insights on the major opportunities and strategies in the antibody drug conjugates market, request a sample here.

For detailed insights on antibody drug conjugates market's relation to the overall economy and other similar markets, request a sample here.

For detailed insights on the mergers and acquisitions in the antibody drug conjugates industry, request a sample here.

For detailed insights on the key dynamics influencing the antibody drug conjugates market growth and SWOT analysis of the antibody drug conjugates industry, request a sample here.